Precision Biosciences Inc DTIL

NAS: DTIL | ISIN: US74019P1084 1/05/2025

5,720 USD (+1,42%)

(+1,42%) 1/05/2025

Toon enkel gratis nieuws

25 januari 2022 · Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments · Persbericht

18 maart 2021 · Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update · Persbericht

12 maart 2021 · Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021 · Persbericht

19 februari 2021 · Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates · Persbericht

19 januari 2021 · Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma · Persbericht

7 januari 2021 · Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe